According to the WHO 2021 classification, GBM is strictly defined as a Grade IV astrocytoma that is IDH-wildtype, reinforcing its aggressive nature, invasive properties, and treatment resistance. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).